News

In an interview with Targeted Oncology, Nilanjan Ghosh, MD, discussed the current challenges in using CAR T-cell therapy as treatment of patients with DLBCL and considers the next steps for this research.

In an interview with Targeted Oncology, Thomas E. Hutson, DO, PharmD, discussed the difficult-to-treat nccRCC patient population and the promise of lenvatinib plus everolimus, as well as other combination regimens.

The partial clinical hold placed by the FDA on the phase 1 chimeric antigen receptor T-cell clinical trial, MELANI-01, has now been lifted.

During a Targeted Oncology Case Based Peer Perspective event, Marc Hoffman, MD, reviewed the case of a 53-year-old woman with relapsed chronic lymphocytic leukemia.

The FDA has granted a Fast Track designation to rilzabrutinib, an oral investigational Bruton’s tyrosine kinase inhibitor, for the treatment of immune thrombocytopenia. The drug was previously granted Orphan Drug designation for this indication.

In an interview with Targeted Oncology, Sarki Abdulkadir, MD, PhD, discussed the emerging role of the MYC protein as a target for the treatment of patients with prostate cancer.

The primary end point of overall survival with tislelizumab compared with docetaxel as the second- or third-line treatment of patients with locally advanced or metastatic non–small cell lung cancer who progressed on previous platinum-based chemotherapy.

In an interview with Targeted Oncology, Alexander Spira, MD, PhD, discussed the role of identifying biomarkers in patients with lung cancer based on the vast amount of data and significant number of approved therapies available for biomarker-driven disease.

During a Targeted Oncology Case Based Peer Perspective event, Ramez N. Eskander, MD, reviewed the case of a 69-year-old woman with newly diagnosed ovarian cancer.

The oral small molecule FLX475 demonstrated promise when administered either alone or in combination with the immune checkpoint inhibitor pembrolizumab in multiple solid tumors, according to findings from a phase 1/2 dose-escalation and expansion study.

The Access to Comprehensive Genomic Profiling Coalition has been formed by 7 leading diagnostic companies and laboratory providers across the United States to advocate for appropriate broad health insurance coverage of comprehensive genomic profiling for patients with advanced-stage cancer.

The FDA will not complete its review of the Biologics License Application for lisocabtagene maraleucel for the treatment of patients with relapsed/refractory large B-cell lymphoma after 2 prior lines of therapy by the Prescription Drug User Fee Act action date of November 16, 2020.

Plinabulin in combination with pegfilgrastim demonstrated a significant improvement in cycle 1 in the rate of prevention of grade 4 neutropenia due to chemotherapy treatment in patients with cancer in the phase 3 PROTECTIVE-2 trial.

New data showed the Helio Liver Test demonstrated high accuracy and screening value of this cell-free DNA methylation blood-based assay for the detection of hepatocellular carcinoma.

In patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), findings from the ongoing phase 2 SPiReL study demonstrated that certain gene expressions are associated with response to DPX-Survivac plus pembrolizumab and intermittent, low-dose cyclophosphamide.

Treatment with the investigation agent INBRX-109 induced responses and decreased the tumor burden in a cohort of patients with chondrosarcoma, according to interim efficacy and safety findings a phase 1 trial in patients with chondrosarcoma, Inhibrx, Inc announced in a press release.

A review of the trending news in oncology online for the week of November 13, 2020, including recent news from the FDA on the cancer treatment paradigm, updates in oncology, and the latest information regarding COVID-19.

The FDA granted approval to pembrolizumab in combination with chemotherapy as treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer whose tumors express PD-L1.

In an interview with Targeted Oncology following the announcement of the FDA approval of azacitidine plus venetoclax in older patients with acute myeloid leukemia, Brian Jonas, MD, provided insight on the VILAE-A study results. He also gave expert advice on how to approach treating older patients with acute myeloid leukemia in every day practice.

In an interview with Targeted Oncology, John L. Marshall, MD, provided an overview of the evolution of treatments for patients with pancreatic cancer, as well as the current therapeutic approaches for these patients and what’s next for this treatment paradigm.

A new retrospective analysis has suggested that the R-CHOP chemotherapy regimen of rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone leads to superior outcomes compared to rituximab plus bendamustine in patients with grade 3A follicular lymphoma.

A total of 100,000 patients are now enrolled Centers for Medicare & Medicaid Innovation’s Oncology Care Model, as a result of the efforts of The US Oncology Network.

Regulatory applications have been submitted to the FDA and European Medicines Agency seeking approval of a subcutaneous form of daratumumab in combination with pomalidomide and dexamethasone as treatment of patients with relapsed or refractory multiple myeloma who have received at least 1 previous therapy.

The combination of ipilimumab with nivolumab induced an objective response rate of 12% as treatment of patients with thyroid cancer.

Three efficacy end points met pre-specified statistical significance in the phase 2 FIGHT study of bemarituzumab plus modified FOLFOX6 in patients with FGFR2b-positive non-HER2-positive frontline advanced gastric or gastroesophageal junction cancer.

In an interview with Targeted Oncology, Anant Ramaswamy, MD, discussed the findings from the phase 2 study of capecitabine plus irinotecan compared with irinotecan alone as treatment of patients with advanced gallbladder cancer.

The strategy of adding the plasmid IL-12 agent tavokinogene telseplasmid to pembrolizumab led to deep systemic responses in patients with actively progressing anti–PD-1–refractory advanced melanoma, according to interim results from the KEYNOTE-695 clinical trial.

A phase 3 study was initiated for a head-to-head comparison of trastuzumab deruxtecan versus T-DM1 as adjuvant treatment of a subset of patients with HER2-positive early breast cancer.

Lenvatinib in combination with everolimus improved progression-free survival in patients with advanced renal cell carcinoma compared with sunitinib, meeting the primary end point of the phase 3 KEYNOTE-581/CLEAR clinical trial. Pembrolizumab added to lenvatinib, another experimental arm of the trial, also achieved a satisfactory overall response rate, meeting a key secondary end point.

The phase 3 KEYNOTE-598 study of pembrolizumab plus ipilimumab in a population of patients with metastatic non–small cell lung cancer has been discontinued for futility.